EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release…
Biotechnology
US, Watertown [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about EyePoint Pharmaceuticals, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2015 | 2.1600 | -0.400 | 26 | 26 | 6 | -15 | -20 | -26 | -7 | -26 | 8 | 41 |
| 2016 | -6.8100 | -6.150 | 1 | 2 | -21 | -239 | -17 | -2 | -22 | -2 | 9 | 4 |
| 2017 | -5.2300 | -5.133 | 7 | 7 | -18 | -199 | -18 | -7 | -18 | -7 | 11 | 11 |
| 2018 | -11.5000 | -11.500 | 2 | 2 | -53 | -447 | -36 | -2 | -44 | -2 | 13 | 4 |
| 2019 | - | -5.675 | - | 18 | - | -220 | - | -18 | - | -18 | - | 28 |
| 2020 | -6.0400 | -1.820 | 20 | 45 | -62 | -70 | -48 | -45 | -47 | -45 | 47 | 69 |
| 2021 | -4.1000 | -1.954 | 34 | 35 | -52 | -76 | -35 | -35 | -37 | -35 | 46 | 54 |
| 2022 | -2.2200 | -2.185 | 36 | 41 | -63 | -61 | -50 | -56 | -55 | -57 | 53 | 63 |
| 2023 | -3.3400 | -1.938 | 41 | 40 | -124 | -70 | -96 | -57 | -78 | -58 | 60 | 62 |
| 2024 | - | -2.221 | - | 42 | - | -82 | - | -42 | - | -42 | - | 64 |
| 2025 | - | -2.577 | - | 14 | - | -101 | - | -14 | - | -14 | - | 22 |
| 2026 | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F11X/td> | - | 2.F111/td> | - | 2.F111 | - | 2.F111 |
| 2027 | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F12X/td> | - | 1.F121/td> | - | 1.F121 | - | 1.F121 |
| 2028 | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F13X/td> | - | 0.F131/td> | - | 0.F131 | - | 0.F131 |